If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Mumbai Celebrates 10 Year Anniversary and Announces Construction of New Facility

    Quick Contact
    • Aptar Pharma
    Aptar Mumbai Celebrates 10 Year Anniversary and Announces Construction of New Facility
    Asia, South Asia, India, Health

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, recently announced the construction of a new facility in India at a ceremony to also celebrate Aptar Mumbai’s ten year anniversary.

    Stephan Tanda, Aptar President and CEO and Kanwal Tikoo, President, India and SEA, Aptar, along with members of Aptar’s executive committee, virtually welcomed Aptar employees who joined from all over the world to witness the groundbreaking of the new facility at Taloja, Mumbai.

    The ceremony took place on January 21, 2022, marking the tenth anniversary of manufacturing at Aptar Mumbai which first began with the assembly of metered dose valves and pumps. Aptar Pharma’s expansion plans in Mumbai will further increase its manufacturing capacity, including the addition of molding capabilities to offer more innovative product solutions to pharma customers in South East Asia.

    The new Aptar Mumbai facility is in line with Aptar’s localization strategy and is a direct response to continuing customer demand in the region.

    “Over the years, our Pharma business in India has shown robust growth and so, in order to serve the needs of our Indian customers, we are enhancing our manufacturing capabilities. Our new facility is a key step that strengthens our competitive position and brings global technology to India, which will ultimately benefit patients," said Stephan Tanda, Aptar President and CEO.

    Kanwal Tikoo, President, India and SEA, Aptar added, “Aptar Pharma has established market leadership position as a pharma packaging solutions company and we continue to grow our influence in this part of the world as the go-to drug delivery expert. We continue to help our customers succeed and patients to live a better life.”

    These sentiments were echoed by Xiangwei Gong, President, Aptar Asia, Gael Touya, President, Aptar Pharma and Alex Theodorakis, President, Aptar Pharma Prescription, who also spoke at the inaugural ceremony and commented on Aptar Pharma’s decade of success in India, which they described as both a key pillar in the pharma ecosystem and a new chapter of growth in the region.

    The new Aptar Mumbai facility, which is being built on a 3.5 acre site at the Palava Industrial and Logistics Park at Taloja, Mumbai, will generate further employment opportunities, with construction expected to be completed by Q1, 2023.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 11 Feb 2022
    • Hits 839
    Sun-Rain
    APG
    Epopack